Author:
Beelen D W,Trenschel R,Casper J,Freund M,Hilger R A,Scheulen M E,Basara N,Fauser A A,Hertenstein B,Mylius H A,Baumgart J,Pichlmeier U,Hahn J R,Holler E
Publisher
Springer Science and Business Media LLC
Subject
Transplantation,Hematology
Reference26 articles.
1. Harstrick A, Wilke H, Eberhardt W et al. A phase I dose escalation trial of intravenous treosulfan in refractory cancer. Onkologie 1996; 19: 153–156.
2. Scheulen ME, Hilger RA, Oberhoff C et al. Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies. Clin Cancer Res 2000; 6: 4209–4216.
3. Baynes RD, Dansey RD, Klein JL et al. A phase I trial of escalating treosulfan in combination with high-dose melphalan and dacarbazine (TMD) with peripheral blood progenitor cell transplant (PBPCT) in recurrent metastatic ovarian and breast cancer. Blood 2000; 96: 170a (Abstr. 731).
4. Westerhof GR, Ploemacher RE, Boudewijn A et al. Comparison of different busulfan analogues for depletion of hematopoietic stem cells and promotion of donor-type chimerism in murine bone marrow transplant recipients. Cancer Res 2000; 60: 5470–5478.
5. Ploemacher RE, Westerhof GR, Blokland I et al. Treosulfan as an alternative conditioning agent in bone marrow transplantation. Bone Marrow Transplant 2000; 25 (Suppl. 1) (Abstr. P421).
Cited by
92 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献